Millennium Appoints Kenneth E. Weg, Former Vice Chairman of Bristol-Myers Squibb, to Board of Directors

Apr 02, 2001, 01:00 ET from Millennium Pharmaceuticals, Inc.

    CAMBRIDGE, Mass., April 2 /PRNewswire/ -- Millennium Pharmaceuticals, Inc.
 (Nasdaq: MLNM) today announced the appointment of Kenneth E. Weg to its Board
 of Directors.  Mr. Weg had a thirty-eight year career with Bristol-Myers
 Squibb, a preeminent global pharmaceutical company, most recently serving as
 vice chairman.  Upon his retirement from Bristol-Myers Squibb in February
 2001, Mr. Weg has served as founder and chairman of Clearview Projects, Inc.
 In this role, Mr Weg is engaged in partnering and deal transaction services to
 biopharmaceutical companies and academic institutions.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
     Mr. Weg, 62, joined Bristol-Myers Squibb in 1969 and held a range of
 senior leadership roles throughout his tenure with the company. He was
 President of Pharmaceutical Operations from 1991 to 1993 where he was
 responsible for Bristol-Myers Squibb's worldwide pharmaceutical business.
 From 1993 to 1996 Mr. Weg was President of the Pharmaceutical Group overseeing
 the pharmaceutical research operations and developing the division's strategic
 direction.  He was President of Worldwide Medicines Group from 1997 to 1998
 and was elected to the Board of Bristol-Myers Squibb in 1995, becoming Vice
 Chairman in 1999.
     "As we deliver on the promise of personalized medicine and our pipeline
 matures downstream, Millennium will continue to evolve in its commercial and
 marketing activities," said Mark Levin, chief executive officer of Millennium.
 "The addition of Mr. Weg's expertise in managing pharmaceutical businesses and
 marketing pharmaceutical products will be extremely valuable to Millennium as
 we build the biopharmaceutical company of the future."
     "Millennium's drive to create breakthrough therapeutic and predictive
 medicine products is very exciting," said Mr. Weg.  "I welcome the opportunity
 to work with the board of directors to guide Millennium as the company strives
 to deliver innovative products that will change the practice of medicine."
     Mr. Weg received a B.S. from Dartmouth College and a M.B.A. from Columbia
 University.  He currently serves on the Board of Directors of Fox Chase Cancer
 Center in Philadelphia, PA.
 
     Millennium, a leading biopharmaceutical company, applies its comprehensive
 and integrated science and technology platform for the discovery and
 development of breakthrough therapeutic and predictive medicine products, with
 a goal of delivering personalized medicine. Through the industrialization of
 this gene-to-patient platform, Millennium is also striving to accelerate the
 process of drug discovery and development. Headquartered in Cambridge, Mass.,
 Millennium currently employs more than 1,300 people.
 
     This press release contains "forward-looking statements," including
 Millennium's expectations of future industry conditions, strategic plans and
 forecasts of operational results. Various risks may cause Millennium's actual
 results to differ materially, including: uncertainties about its drug
 discovery and clinical development processes, uncertainties about obtaining
 patent protection for its discoveries and about the commercial limitations
 imposed by patents owned or controlled by third parties; Millennium's
 dependence upon strategic alliance partners to develop and commercialize
 products and services based on its work; uncertainties about obtaining
 regulatory approvals to market products and services resulting from its
 development efforts; and the requirement for substantial funding to conduct
 research and development and to expand commercialization activities. For a
 further list and description of such risks and uncertainties, see the reports
 filed by Millennium with the Securities and Exchange Commission. Millennium
 disclaims any intention or obligation to update or revise any forward-looking
 statements, whether as a result of new information, future events or
 otherwise.
     Editor's Note: This release is available on Millennium's website at
 www.millennium.com.
 
     Contacts:
     Gina Brazier (investor)
     (617) 551-3611
     Maureen Suda (media)
     (617) 551-2959
 
 

SOURCE Millennium Pharmaceuticals, Inc.
    CAMBRIDGE, Mass., April 2 /PRNewswire/ -- Millennium Pharmaceuticals, Inc.
 (Nasdaq: MLNM) today announced the appointment of Kenneth E. Weg to its Board
 of Directors.  Mr. Weg had a thirty-eight year career with Bristol-Myers
 Squibb, a preeminent global pharmaceutical company, most recently serving as
 vice chairman.  Upon his retirement from Bristol-Myers Squibb in February
 2001, Mr. Weg has served as founder and chairman of Clearview Projects, Inc.
 In this role, Mr Weg is engaged in partnering and deal transaction services to
 biopharmaceutical companies and academic institutions.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
     Mr. Weg, 62, joined Bristol-Myers Squibb in 1969 and held a range of
 senior leadership roles throughout his tenure with the company. He was
 President of Pharmaceutical Operations from 1991 to 1993 where he was
 responsible for Bristol-Myers Squibb's worldwide pharmaceutical business.
 From 1993 to 1996 Mr. Weg was President of the Pharmaceutical Group overseeing
 the pharmaceutical research operations and developing the division's strategic
 direction.  He was President of Worldwide Medicines Group from 1997 to 1998
 and was elected to the Board of Bristol-Myers Squibb in 1995, becoming Vice
 Chairman in 1999.
     "As we deliver on the promise of personalized medicine and our pipeline
 matures downstream, Millennium will continue to evolve in its commercial and
 marketing activities," said Mark Levin, chief executive officer of Millennium.
 "The addition of Mr. Weg's expertise in managing pharmaceutical businesses and
 marketing pharmaceutical products will be extremely valuable to Millennium as
 we build the biopharmaceutical company of the future."
     "Millennium's drive to create breakthrough therapeutic and predictive
 medicine products is very exciting," said Mr. Weg.  "I welcome the opportunity
 to work with the board of directors to guide Millennium as the company strives
 to deliver innovative products that will change the practice of medicine."
     Mr. Weg received a B.S. from Dartmouth College and a M.B.A. from Columbia
 University.  He currently serves on the Board of Directors of Fox Chase Cancer
 Center in Philadelphia, PA.
 
     Millennium, a leading biopharmaceutical company, applies its comprehensive
 and integrated science and technology platform for the discovery and
 development of breakthrough therapeutic and predictive medicine products, with
 a goal of delivering personalized medicine. Through the industrialization of
 this gene-to-patient platform, Millennium is also striving to accelerate the
 process of drug discovery and development. Headquartered in Cambridge, Mass.,
 Millennium currently employs more than 1,300 people.
 
     This press release contains "forward-looking statements," including
 Millennium's expectations of future industry conditions, strategic plans and
 forecasts of operational results. Various risks may cause Millennium's actual
 results to differ materially, including: uncertainties about its drug
 discovery and clinical development processes, uncertainties about obtaining
 patent protection for its discoveries and about the commercial limitations
 imposed by patents owned or controlled by third parties; Millennium's
 dependence upon strategic alliance partners to develop and commercialize
 products and services based on its work; uncertainties about obtaining
 regulatory approvals to market products and services resulting from its
 development efforts; and the requirement for substantial funding to conduct
 research and development and to expand commercialization activities. For a
 further list and description of such risks and uncertainties, see the reports
 filed by Millennium with the Securities and Exchange Commission. Millennium
 disclaims any intention or obligation to update or revise any forward-looking
 statements, whether as a result of new information, future events or
 otherwise.
     Editor's Note: This release is available on Millennium's website at
 www.millennium.com.
 
     Contacts:
     Gina Brazier (investor)
     (617) 551-3611
     Maureen Suda (media)
     (617) 551-2959
 
 SOURCE  Millennium Pharmaceuticals, Inc.